For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() UnitedHealth Group IncorporatedUNH US · Health Care · USD Current price$344.82as of Nov 20, 2026 Summary
Analyst consensusStrong Buy 7Buy 15Hold 425 analysts 3-year price (USD)Factor profileMulti-factor score 70 / 100 Market data
Business descriptionLargest U.S. health care management company: UnitedHealthcare (roughly 50M members; Medicare and retirement about 50% of segment revenue) plus Optum (health delivery, Insight analytics, OptumRx PBM). Sub-industry: Managed Health Care; S&P 500, Large-Cap Value. Competitive moatScale in health plans combined with Optum creates a cost advantage: OptumRx buying power, owned care delivery and Insight analytics lower medical and operating costs, so United is typically the medical cost ratio leader and can bid lower premiums. Optum gets a captive customer base and data (Insight backlog about USD 31.1B). Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Nov 13, 2026
Current price: $344.82 · Nov 20, 2026· USD
CFRA Ratingbuy
TBI Multi Score70
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: UNHBusiness description
Largest U.S. health care management company: UnitedHealthcare (roughly 50M members; Medicare and retirement about 50% of segment revenue) plus Optum (health delivery, Insight analytics, OptumRx PBM). Sub-industry: Managed Health Care; S&P 500, Large-Cap Value.
Competitive moat
Scale in health plans combined with Optum creates a cost advantage: OptumRx buying power, owned care delivery and Insight analytics lower medical and operating costs, so United is typically the medical cost ratio leader and can bid lower premiums. Optum gets a captive customer base and data (Insight backlog about USD 31.1B).
Recent developments
- Q3 2026 (10/13/2026): EPS beat on margins despite membership losses, guidance raised; MA showing early stabilization, Medicaid cost inflation persistent.
- Buyback resumed (at least USD 5B in 2026) after the 2025 suspension; over USD 8B dividends; long-term EPS growth target 13-16%.
- Policy: April 2026 MA final rate notice +2.48%; CMS Stars reform worth about USD 5B for MA insurers in 2028; 2027 Stars at least 69% of members in 4+ star plans (78% in 2026), 5-star plans up to 3 from 2.
- Sector read (11/11/2026): UNH is the largest potential beneficiary of No Surprises Act IDR reform (IDR about 100 bp of medical costs; commercial IDR cost trend +11% Y/Y); CFRA sees low breakup risk but more PBM scrutiny. See Managed Health Care Q3 2026 Earnings & Post-Midterm Policy.
Investment risks / red flags
- Medical utilization spikes, Medicaid funding below inflation, OBBBA Medicaid work requirements (1 Jan 2027).
- PBM legislation; ongoing DOJ investigation into billing practices.
- History: 2024 Change Healthcare cyberattack, CEO Thompson murder, 2025 earnings collapse (EPS 16.35 vs 27.66 in 2024); Hemsley replaced Witty as CEO in May 2025.
- Share price still well below the late-2024 peak; turnaround story.
Market Data
Source: mkts.io · Nov 20, 2026, 16:01 UTC
Key Metrics
P/E (TTM)19.67
P/E (Fwd)14.68
Dividend2.81%
Beta0.52
52W High$461.62
52W Low$255.97
Analyst Consensus
7
15
4
Strong Buy7Buy15Hold425 analysts
Consensus Target$476.36
+38.1% upside
Calendar Events
Next EarningsJan 12, 2027
Ex-DividendDec 7, 2026
Dividend DateDec 15, 2026
Financials
Revenue$450.06B
Rev Growth-0.40%
Earnings Growth76.10%
Gross Margin20.05%
Op Margin5.85%
Profit Margin3.53%
EBITDA$28.90B
ROA5.24%
ROE15.77%
Rev/Share$498.13
Total Cash$28.55B
Total Debt$74.33B
D/E Ratio70.43
Free Cash Flow$26.50B
Op Cash Flow$26.19B
Current Ratio0.74
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 2.28 | $112.40B |
| +1q | 8.15 | $113.79B |
| 0y | 20.61 | $449.01B |
| +1y | 23.47 | $463.14B |
Earnings
Quarterly EPS
4Q2025
Est: 2.112.11Beat
1Q2026
Est: 6.607.23Beat
2Q2026
Est: 4.926.38Beat
3Q2026
Est: 4.144.69Beat
Annual
2022
Rev $324.16BEarn $20.12B
2023
Rev $371.62BEarn $22.38B
2024
Rev $400.28BEarn $14.40B
2025
Rev $447.57BEarn $12.06B
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Oct 27, 2026 | Wells Fargo | main | Overweight |
| Oct 27, 2026 | Morgan Stanley | main | Overweight |
| Oct 22, 2026 | Mizuho | main | Outperform |
| Oct 20, 2026 | RBC Capital | main | Outperform |
| Oct 16, 2026 | Bernstein | main | Outperform |
| Oct 16, 2026 | JP Morgan | main | Overweight |
